Efficacy of ledipasvir and Sofosbuvir in Patients with Hepatitis C Virus

Hazim Makki Hameed Hameed; Abdullah Zuhair Alyouzbaki; Nawal M Al Khalidi

doi:10.24321/doi.org/10.24321/0019.5138.202599

Hazim Makki Hameed Hameed Lecturer of Medicine, College of Medicine, University of Mosul
Abdullah Zuhair Alyouzbaki Lecturer of Medicine, College of Medicine, University of Mosul
Nawal M Al Khalidi Consultant Gastroenterologist & Hepatologist , Chairperson of the Scientific Council for Gastenterology & Hepatology of Arab Board for Health Specialization

DOI: https://doi.org/10.24321/doi.org/10.24321/0019.5138.202599

Keywords: Hepatitis C Virus, Hcv Genotypes, Liver Cirrhosis

Abstract

ABSTRACT

Background: Treatment of hepatitis C virus (HCV) infection has witnessed a dramatic improvement during the last several years after the introduction of direct acting antiviral drugs (DAAs). One of the initial DAAs is the combination of ledipasvir and sofosbuvir (Led/Sof).

Aims: The aim of this study is to evaluate the efficacy of Led/Sof in treating patients with HCV infections and identify common HCV genotypes .

Patients and Methods: This is a retrospective study conducted over a period of 15 months and include 122 patients with HCV infection. All patients underwent HCV polymerase chain reaction (PCR) and genotyping at the time of diagnosis. Just patients with genotype (GT) 1 and 4 were included and other genotypes were excluded. All patients received a fixed-dose combination tablet of Led/Sof (Harvoni brand, 90 mg ledipasvir and 400 mg sofosbuvir) once daily for 12 weeks. HCV PCR was repeated 12 weeks after finishing treatment with Led/Sof to assess the sustained virological response (SVR).

Results: The overall SVR was 95.08%; the best SVR was associated with GT 4 (96.67%), followed by GT1a (93.88%) and GT1b (92.31%). Those with treatment naïve (TN) patients had SVR of 94.85%, and those with treatment experienced (TE) patients had SVR of 96%. Non-cirrhotic patients had much better SVR (98.02%) than cirrhotic patients, including both compensated (76.92%) and decompensated (87.5%) liver cirrhosis . HCV GT 4 was the most common genotype in Baghdad (60 patients, 49.2%), followed by GT 1a (49 patients, 40.2%) and GT 1b (13 patients, 10.6%).

Conclusions

Led/Sof (Harvoni) had high SVR in different HCV genotypes, particularly GT4 . Led/Sof is equally effective in both treatment-naïve and treatment-experienced patients. Cirrhotic- patients had lower SVR than non-cirrhotic patients .GT 4 is the most prevalent HCV genotype .

References

1. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016; 388: 1081–1088.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 2014; 61, S45–S57.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57, 1333–1342.
4. WHO Fact Sheet. Hepatitis C. Updated June 24, 2022. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
5. Hepatitis C — one pill fits all? Nat. Rev. Drug Discov. 2013; 12, 595–610.
6. Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D , et al.Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. J. Viral Hepat. 2013; 20, 524–529.
7. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection with Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62(6):683-694. doi:10.1093/cid/civ948
8. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E , et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2014;12, 1349–1359.e13
9. Borgia SM, Hedskog C, Parhy B, et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018;218(11):1722-1729. doi:10.1093/infdis/jiy401
10. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2017; 2, 161–176.
11. Alyouzbaki, A., Mohammed, A., Al Obeidy, B., Issa, S., Alsayyid, R., Husssien, W. Hepatitis C Virus genotypes in Nineveh Governorate. The Medical Journal of Basrah University, 2024; 42(1): 99-107. doi: 10.33762/mjbu.2024.146721.1193
12. Ministry of Health and Population, El-Zanaty and Associates & ICF International. Egypt health issues survey 2015.DHS Program.
13. Ramadhan AA. Prevalence of hepatitis B and hepatitis c virus infections at premarital screening program in Duhok, Iraq. Duhok Med J 2018; 12(1), 13-23.
14. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J ,et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral Hepat. 21 (Suppl. 1) 2014; 34–59.
15. Hassanein TI, Wyles DL, Wang S, Kwo PY, Shiffman ML, Younes Z, et al., eds. Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4). In vitro. 2016; 2:3.
16. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm — volume 2. J. Viral Hepat. 22 (Suppl. 1) 2015, 26–45.
17. Schmidt AJ, Falcato L, Zahno B, Burri A, Regenass S, Müllhaupt B, et al. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? BMC Public Health 14, 3 (2014).
18. Lo CC, Huang CF, Cheng PN, et al. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. J Formos Med Assoc. 2022;121(8):1567-1578. doi:10.1016/j.jfma.2022.01.012
19. U.S. Preventive Services Task Force. Hepatitis C: screening. U.S. Preventive Services Task Force http://www.uspreventiveservicestaskforce.org/uspstf/ uspshepc.htm (2013).
20. Penin F, Dubuisson J, Rey FA, Moradpour D& Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39, 5–19.
21. André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M , et al. Characterization of low- and very-lowdensity hepatitis C virus RNA-containing particles. J. Virol. 2002; 76, 6919–6928 .
22. Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr. Top. Microbiol. Immunol. 2013; 369, 87–112
23. Aasld-Idsa H. Guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3):932-54.
24. Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017; 77(2):131-44.
25. Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018 Apr; 33(4):551-557.
26. Bourliere M, Gordon SC, Ramji A, Ravendhran N, Tran TT, Hyland RH, et al. Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks as a Salvage regimen in NS5A inhibitor-experienced patients with genotype 1–6 infection: the phase 3 POLARIS-1 study. Hepatology. 2016; 64:1–136.
27. Wyles DL, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. SURVEYOR-II, part 3: efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis. In Vitro. 2016; 1:2.